FDA Issues New Guidance for Drug Delivery Device Data
The draft document standardizes the technical performance data required for drug and biological delivery product applications.
Updated on Oct. 29, 2026 in Biotech
Live Poll
Do you support stricter FDA oversight of drug delivery devices for patients?
In October 2026, the FDA released new draft guidance defining performance characteristics for devices and combination products used to deliver human drugs. The document provides a standardized framework for data submissions across investigational, marketing, and post-market change applications.
Why it matters
This guidance clarifies the regulatory expectations for drug delivery hardware, aiming to ensure consistent performance data that developers must provide throughout the product lifecycle. It represents an effort to streamline the evidence required for combination product approvals in the United States.
The draft guidance specifies the performance data requirements for developers, contrasting with previous application processes that lacked standardized benchmarks. It focuses on the technical documentation necessary to validate that devices deliver drugs and biological products as intended.
The players
FDA
The federal agency responsible for protecting public health in the United States by ensuring the safety and efficacy of human drugs, biological products, and medical devices.
The details
The guidance details the specific information required to demonstrate that a device effectively administers its payload. It targets combination products—medical devices paired with drugs or biologics—that must meet uniform standards for investigational and marketing applications. By standardizing these requirements, the FDA aims to reduce ambiguity in technical filings for developers during the regulatory review process.
Timeline
October 2026: The FDA published the draft guidance for the pharmaceutical and device industry.
The Tech Race
This draft guidance updates the implementation standards for existing regulatory review pathways established under the agency's combination product oversight mandate. It reflects a broader effort to standardize technical benchmarks for hardware-drug integration, which is currently a high-priority area for biotech innovation.
Device developers and biotech firms must now align their technical documentation with these new FDA criteria for any upcoming marketing or change applications. This shift potentially simplifies long-term compliance workflows for companies managing legacy and next-generation delivery hardware.
The takeaway
The FDA is narrowing the performance reporting gaps for combination products, signaling a move toward more uniform data standards in drug delivery. Developers should monitor the agency's portal for the finalization of these guidelines and subsequent updates to submission protocols.
Further reading
For broader context on how regulatory standards are influencing product development, see the Biotech section.
More information
View the complete official FDA guidance document page for full technical requirements.
Source note: This article includes information reported by U.S. Food and Drug Administration.
Live Poll
Do you support stricter FDA oversight of drug delivery devices for patients?
